Vendor review
Dankang BioHealth reviews
Dankang BioHealth reviews from 94 independent lab tests (Retatrutide, Tirzepatide and Tesamorelin): grade A, purity and fill accuracy. Is Dankang BioHealth legit? See what its vials showed.
What the lab tests show
94 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Sep 23, 2026 | Retatrutide | 99.9 % | 28.1 mg of 30 mg (-6 %) | Pass | View |
| Sep 23, 2026 | Retatrutide | 99.9 % | 15.8 mg of 20 mg (-21 %) | Pass | View |
| Sep 20, 2026 | BPC-157 | 99.99 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Sep 15, 2026 | TB-500 | 99.9 % | 9.45 mg of 10 mg (-6 %) | Pass | View |
| Sep 14, 2026 | SS-31 | 99.4 % | 48.8 mg of 50 mg (-2 %) | Pass | View |
| Jul 20, 2026 | Retatrutide | 99.8 % | 9.7 mg of 10 mg (-3 %) | Pass | View |
| Jul 20, 2026 | BPC-157 | 99.3 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Jul 10, 2026 | KLOW | 80 mg | Fail | View | |
| Jul 1, 2026 | BPC-157 | 10 mg | Fail | View | |
| Jul 1, 2026 | GHK-Cu | 99.9 % | 33.2 mg of 50 mg (-34 %) | Pass | View |
| Jul 1, 2026 | TB-500 | 10 mg | Fail | View | |
| Jul 1, 2026 | MOTS-c | 98.7 % | 9.43 mg of 10 mg (-6 %) | Pass | View |
| Jul 1, 2026 | SS-31 | 50 mg | Fail | View | |
| Jun 24, 2026 | Retatrutide | 99.9 % | 11.6 mg of 10 mg (16 %) | Pass | View |
| Jun 17, 2026 | Tirzepatide | 5 mg | Fail | View | |
| Jun 17, 2026 | Retatrutide | 5 mg | Fail | View | |
| Jun 1, 2026 | Retatrutide | 99.9 % | 18.8 mg of 20 mg (-6 %) | Pass | View |
| Jun 1, 2026 | TB-500 | 99.6 % | 8.37 mg of 10 mg (-16 %) | Pass | View |
| Jun 1, 2026 | GHK-Cu | 99.9 % | 86.6 mg of 100 mg (-13 %) | Pass | View |
| May 27, 2026 | BPC-157 | 99.9 % | 8.59 mg of 10 mg (-14 %) | Pass | View |
| May 27, 2026 | Retatrutide | 99.9 % | 14.5 mg of 30 mg (-52 %) | Pass | View |
| May 27, 2026 | TB-500 | 10 mg | Fail | View | |
| May 27, 2026 | Tesamorelin | 99.7 % | 11.9 mg of 10 mg (19 %) | Pass | View |
| May 25, 2026 | Retatrutide | 99.6 % | 15 mg of 15 mg (0 %) | Pass | View |
| May 15, 2026 | Retatrutide | 30 mg | Fail | View | |
| May 13, 2026 | KLOW | 80 mg | Fail | View | |
| May 8, 2026 | Retatrutide | 94.9 % | 4.65 mg of 5 mg (-7 %) | Pass | View |
| May 8, 2026 | Retatrutide | 99.9 % | 22.1 mg of 30 mg (-26 %) | Pass | View |
| May 7, 2026 | KLOW | 99.5 % | 42.72 mg of 80 mg (-47 %) | Pass | View |
| May 6, 2026 | Tirzepatide | 5 mg | Fail | View | |
| May 6, 2026 | NAD+ | 95.9 % | 1110 mg of 1000 mg (11 %) | Pass | View |
| May 6, 2026 | Retatrutide | 99.9 % | 47.6 mg of 50 mg (-5 %) | Pass | View |
| May 6, 2026 | Tesamorelin | 99.9 % | 8.67 mg of 10 mg (-13 %) | Pass | View |
| Apr 30, 2026 | Retatrutide | 99.8 % | 18.9 mg of 20 mg (-6 %) | Pass | View |
| Apr 30, 2026 | Tirzepatide | 99.7 % | 34.1 mg of 30 mg (14 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 19.8 mg of 20 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 8.48 mg of 10 mg (-15 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 99.9 % | 5.36 mg of 10 mg (-46 %) | Pass | View |
| Apr 28, 2026 | NAD+ | 98.2 % | 564 mg of 500 mg (13 %) | Pass | View |
| Apr 28, 2026 | NAD+ | 98.5 % | 1310 mg of 1000 mg (31 %) | Pass | View |
| Apr 28, 2026 | MOTS-c | 98.5 % | 19.7 mg of 20 mg (-2 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 19.1 mg of 20 mg (-4 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 98.6 % | 5.65 mg of 5 mg (13 %) | Pass | View |
| Apr 27, 2026 | BPC-157 | 10 mg | Fail | View | |
| Apr 26, 2026 | Retatrutide | 99.9 % | 7.04 mg of 10 mg (-30 %) | Pass | View |
| Apr 26, 2026 | Retatrutide | 10 mg | Fail | View | |
| Apr 26, 2026 | MOTS-c | 99.1 % | 63.6 mg of 40 mg (59 %) | Pass | View |
| Apr 26, 2026 | MOTS-c | 98.1 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Apr 26, 2026 | MOTS-c | 98.8 % | 8.65 mg of 10 mg (-14 %) | Pass | View |
| Apr 24, 2026 | NAD+ | 99 % | 1,040 mg of 1000 mg (4 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 17.5 mg of 20 mg (-13 %) | Pass | View |
| Apr 23, 2026 | TB-500 | 98.3 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Apr 21, 2026 | Retatrutide | 99.6 % | 22.7 mg of 30 mg (-24 %) | Pass | View |
| Apr 2, 2026 | CJC-1295 | 99.4 % | 6.6 mg of 5 mg (32 %) | Pass | View |
| Mar 25, 2026 | Tesamorelin | 99.6 % | 5.1 mg of 10 mg (-49 %) | Pass | View |
| Mar 25, 2026 | GHK-Cu | 99.7 % | 79.2 mg of 100 mg (-21 %) | Pass | View |
| Mar 25, 2026 | Tirzepatide | 99.8 % | 28 mg of 15 mg (87 %) | Pass | View |
| Mar 25, 2026 | SS-31 | 99.9 % | 55.9 mg of 50 mg (12 %) | Pass | View |
| Mar 12, 2026 | NAD+ | 99.7 % | 523 mg of 500 mg (5 %) | Pass | View |
| Mar 10, 2026 | GHK-Cu | 99.7 % | 90.4 mg of 100 mg (-10 %) | Pass | View |
What Dankang BioHealth sells
No current listings on record.
About Dankang BioHealth
whastsapp +852 5517 2389